
Max Healthcare Q3 FY24 Earnings Call Analysis
Revenue, margin, capex, fundraise and order book outlook from management commentary.
Management growth scorecard
Revenue
Category 3
Margin
Category 3
Fundraise
N/A
Order
N/A
Capex
Yes
1 of 3 growth signals are positive — mixed outlook.
Full analysisRevenue guidance
Category 3- Network gross revenue grew 16% YoY for the nine months ended Dec 2023; Q3 revenue grew 14% YoY.
- Average Revenue Per Occupied Bed (ARPOB) is expected to grow reasonably at 9-10% driven by price increases, OPD growth, oncology growth, and improved case/channel mix.
- International patient revenue grew 25% YoY, supporting revenue growth.
- Expansion adding around 800-1000 beds over next 5-6 years expected to be quickly absorbed due to high demand and occupancy constraints.
- Brownfield expansions like Shalimar Bagh show new beds ramp up quickly and contribute positive EBITDA and operating margins.
- Oncology, including robotics and immunotherapy, is a key growth driver, with higher EBITDA per bed.
- Institutional business tariffs may be revised upwards, potentially increasing revenue.
- Seasonal patterns: Q2 & Q4 typically strongest quarters.
- Overall, a robust Q4 is expected due to seasonality and continued growth momentum.
See what Max Healthcare management said on margin guidance — free account, 30 seconds.
Fundraise plans
- There is no explicit mention of any current or immediate new fundraising through debt or equity in the provided pages.
- The company highlights strong free cash flow generation (Rs. 924 crore over nine months), which is being used for expansion and dividends.
- Expansion projects (Dwarka, Nanavati, Gurgaon, Mohali, Saket Complex) are largely funded through internal cash flows, with no indication of new external financing.
- Abhay Soi mentioned having sufficient wherewithal to add 3-4 hospitals within 1-2 years without stressing the balance sheet.
- For Lucknow, large-scale future capacity expansions post FY28 are described as potential, with no approved CAPEX or Board approvals currently.
- Overall, the company appears financially comfortable funding growth organically without aggressive external fundraising plans at this time.
See what Max Healthcare management said on order book — free account, 30 seconds.
Capex plans
YesTrack Max Healthcare — get its next earnings analysis in your feed
How does Max Healthcare rank vs peers in Healthcare Services?
Pro featureHow does Max Healthcare rank in Healthcare Services?
Compare Max Healthcare against every Healthcare Services company (Q3 FY24) on revenue, margins and earnings-call signals.
Continue your research
What Max Healthcare's management said in earlier quarters
Others in Healthcare Services this season
- Chandan Healthca (Q2 FY27)
Q2 FY27 operating income: ₹57.94 Cr, up 45.04% YoY from ₹39.95 Cr (Page 8) . Key investor presentation takeaways from Chandan Healthcare Ltd's Q2 FY27 investor
- Invicta Diagnostic (Q2 FY27)
Revenue from operations for the half year ended September 30, 2026: ₹379.11 lakhs (Page 4). Key results statement takeaways from Invicta Diagnostic Ltd's Q2 FY2
- Unihealth Hosp (Q2 FY27)
1,270 million with a year-on-year (YoY) growth of 6.3% . Key results statement takeaways from Unihealth Hospitals Ltd's Q2 FY27 results statement — and how it r
- Sangani Hospital (Q2 FY27)
1008.56 lakhs (~11.8% increase). Key results statement takeaways from Sangani Hospitals Ltd's Q2 FY27 results statement — and how it ranks against sector peers.